NCT05821530

Brief Summary

A high-frequency impulse therapy (HFIT) device (Enso, San Francisco, CA) is a portable device for the treatment of musculoskeletal pain. This three-arm randomized controlled trial study compares a HFIT group to a standard transcutaneous electrical nerve stimulator (TENS) group and a control group.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
325

participants targeted

Target at P75+ for not_applicable chronic-pain

Timeline
Completed

Started Apr 2023

Shorter than P25 for not_applicable chronic-pain

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 20, 2023

Completed
4 days until next milestone

Study Start

First participant enrolled

April 24, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

June 8, 2023

Status Verified

June 1, 2023

Enrollment Period

2 months

First QC Date

April 6, 2023

Last Update Submit

June 6, 2023

Conditions

Keywords

musculoskeletalchronicpainknee painback pain

Outcome Measures

Primary Outcomes (1)

  • Pain MCID

    Pain will be measured by the Numeric Pain Rating Scale, ranging from 0 (no pain) to 100 (worst possible pain). The minimal clinically important difference (MCID) of pain will be achieved (0/1) if there is at least a 34% or 23 point improvement, as based on literature.

    Baseline and Week 4

Secondary Outcomes (5)

  • Function MCID (Back)

    Baseline and Week 4

  • Function MCID (Knee)

    Baseline and Week 4

  • Anxiety

    Baseline and Week 4

  • Depression

    Baseline and Week 4

  • Opioid use

    Baseline and Week 4

Study Arms (3)

HFIT

EXPERIMENTAL

Participants received a HFIT device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the HFIT device for at least 1 hour daily for 4 weeks.

Device: HFIT

TENS

EXPERIMENTAL

Participants received a TENS device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the TENS device for at least 1 hour daily for 4 weeks.

Device: TENS

Control

ACTIVE COMPARATOR

Participants took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists.

Other: Control

Interventions

HFITDEVICE

At least 1 hour daily for 4 weeks

Also known as: Enso
HFIT
TENSDEVICE

At least 1 hour daily for 4 weeks

TENS
ControlOTHER

Users will continue to use the digital MSK program as needed

Also known as: Digital MSK program
Control

Eligibility Criteria

Age18 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 or over and under age 65
  • Baseline pain is 40 or more out of 100 on a NPRS
  • Member of digital MSK program's chronic back or knee pain program, after January 1, 2023
  • Member engaged in the most recent 3 weeks
  • Experiencing chronic pain for at least 3 months
  • Subject able to understand and provide informed consent
  • Has an email account

You may not qualify if:

  • Diagnosis of cancer/malignant tumors in the last 5 years
  • Back or knee surgery in the last 6 months
  • Has a cardiac pacemaker, implanted defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other implanted electronic device
  • Patients with history of opioid, alcohol, or drug abuse in the last 1 year
  • Cognitive, behavioral, neurologic, or psychiatric disorder (e.g., dementia, Parkinson's, schizophrenia, stroke) that may interfere with the study or prevent the subject from complying with the requirements of the protocol
  • Pregnant or plan on becoming pregnant in the next year
  • Have epilepsy
  • Have cardiovascular disease
  • Current pain (in the past 24 hours) is less than 40 out of 100 on a NPRS

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hinge Health, Inc

San Francisco, California, 94105, United States

Location

MeSH Terms

Conditions

Chronic PainLow Back PainBronchiolitis Obliterans SyndromePainBack Pain

Interventions

Transcutaneous Electric Nerve Stimulation

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsOrganizing PneumoniaBronchiolitis ObliteransBronchiolitisBronchitisBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesGraft vs Host DiseaseImmune System Diseases

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitationAnalgesiaAnesthesia and Analgesia

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 6, 2023

First Posted

April 20, 2023

Study Start

April 24, 2023

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

June 8, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations